Mark A Cervinski, PhD
Associate Professor of Pathology and Laboratory Medicine
Director of Clinical Chemistry
Director of Point-Of-Care Testing
Diplomate of the American Board of Clinical Chemistry
Fellow, AACC Academy
Pathology and Laboratory Medicine
Ph.D. Biochemistry and Molecular Biology, 2006
University of North Dakota School of Medicine and Health Sciences
Clinical Chemistry Fellowship, 2007-2009
Washington University School of Medicine
Department of Pathology
Dartmouth-Hitchcock Medical Center
One Medical Center Drive
Lebanon NH 03756
Phone: 603 650 7114
Fax: 603 650 4845
General Clinical Chemistry
Laboratory Test Utilization Management
Real Time Patient Based Quality Control
Human Chorionic Gonadotropin
Director of ComACC Accredited Clinical Chemistry Fellowship Program
Lecturer for the Geisel School of Medicine General Pathology Course
Mark Cervinski Ph.D DABCC, originally from Bonnyville, Alberta Canada received his Ph.D. in Biochemistry and Molecular Biology from the University of North Dakota in Grand Forks, North Dakota in 2006. Following his Ph.D. training Dr. Cervinski shifted his focus from the basic sciences to clinical chemistry and completed a Fellowship in Clinical Chemistry from Washington University in St. Louis in the summer of 2009. Mark joined the Department of Pathology and Laboratory Medicine as an Assistant Professor and as the Director of Clinical Chemistry at Dartmouth-Hitchcock Medical Center in August of 2009. Among diverse interests in clinical chemistry and laboratory medicine Dr. Cervinski is currently focused on using patient data as a supplementary quality control strategy, as well as test utilization/optimization and finding efficiencies in delivering laboratory results.
Director of the Clinical Chemistry Fellowship program at DHMC
Review of SARS-CoV-2 Antigen and Antibody Testing in Diagnosis and Community Surveillance.
An Opioid Hiding in Plain Sight: Loperamide-Induced False-Positive Fentanyl and Buprenorphine Immunoassay Results.
Reevaluating the Icterus Index Cutoff of a Jaffe Creatinine Method.
Wastewater-Based SARS-CoV-2 Surveillance in Northern New England.
Comparison of Symptoms and Antibody Response Following Administration of Moderna or Pfizer SARS-CoV-2 Vaccines.
Transformation of Sequential Hospital and Outpatient Laboratory Data into Between-Day Reference Change Values.
Persistently Positive Urine Amphetamines Confirmation Testing.
Retrospective Evaluation of the Antibody Prevalence in Epilepsy and Encephalopathy (APE2) Score.
Pushing Patient-Based Quality Control Forward through Regression.
Gamma Glutamyl Transferase Activity Has Limited Utility in Assessment of Alkaline Phosphatase Elevations.